上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
Nimodipine (Synonyms: 尼莫地平; BAY-e 9736) 纯度: 99.42%
Nimodipine (BAY-e 9736) 是一种具有口服活性,耐受性良好的光敏二氢吡啶钙拮抗剂。Nimodipine 可以用于脑血管疾病的研究。
Nimodipine Chemical Structure
CAS No. : 66085-59-4
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
Free Sample (0.1-0.5 mg) | Apply now | ||
10 mM * 1 mL in DMSO | ¥500 | In-stock | |
100 mg | ¥400 | In-stock | |
500 mg | ¥800 | In-stock | |
1 g | 询价 | ||
5 g | 询价 |
* Please select Quantity before adding items.
Nimodipine 相关产品
•相关化合物库:
- Drug Repurposing Compound Library Plus
- FDA-Approved Drug Library Plus
- FDA-Approved Drug Library Mini
- Bioactive Compound Library Plus
- Membrane Transporter/Ion Channel Compound Library
- Neuronal Signaling Compound Library
- FDA-Approved Drug Library
- Anti-Cancer Compound Library
- CNS-Penetrant Compound Library
- Autophagy Compound Library
- Drug Repurposing Compound Library
- Anti-Cardiovascular Disease Compound Library
- NMPA-Approved Drug Library
- Orally Active Compound Library
- FDA Approved & Pharmacopeial Drug Library
- Neuroprotective Compound Library
- Drug-Induced Liver Injury (DILI) Compound Library
- Rare Diseases Drug Library
生物活性 |
Nimodipine (BAY-e 9736) is an orally active, well-tolerated and light-sensitive dihydropyridine calcium antagonist. Nimodipine can be used for the research of cerebrovascular disorders[1]. |
IC50 & Target |
dihydropyridine calcium[1] |
||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
体外研究 (In Vitro) |
Nimodipine (1.5~150 μg/ml; 15 minutes; B16a and W256 cells) results in a dose-dependent inhibition of B16a and W256 tumor-cell-induced platelet aggregation. Nimodipine is also inhibitory in a homologous system[3]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
体内研究 (In Vivo) |
Nimodipine (0.2 µg/µl, intrathecal administration) prevents subarachnoid hemorrhage-associated cerebral vasospasm by prophylactic continuous intrathecal administration[2]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
|
||||||||||||||||
Clinical Trial |
|
||||||||||||||||
分子量 |
418.44 |
||||||||||||||||
Formula |
C21H26N2O7 |
||||||||||||||||
CAS 号 |
66085-59-4 |
||||||||||||||||
中文名称 |
尼莫地平;硝苯比酯;硝苯甲氧乙基异丙啶 |
||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
储存方式 |
4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 100 mg/mL (238.98 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|
||||||||||||||||
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务